Market capitalization | $94.66m |
Enterprise Value | $59.99m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 5.14 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-98.05m |
Free Cash Flow (TTM) Free Cash Flow | $-85.03m |
Cash position | $35.67m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
7 Analysts have issued a Immunic, Inc. forecast:
7 Analysts have issued a Immunic, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.13 -0.13 |
18%
18%
|
|
EBITDA | -98 -98 |
1%
1%
|
EBIT (Operating Income) EBIT | -98 -98 |
1%
1%
|
Net Profit | -101 -101 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
Head office | United States |
CEO | Daniel Vitt |
Employees | 91 |
Founded | 2003 |
Website | imux.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.